Allergy News
ImVisioN Therapeutics Starts Phase I Clinical Trial Of IVN201 Against Cat Dander Allergy And Raises CHF 4.6 M	11 Sept 2008
Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology	11 Sept 2008